A new method to deliver cancer vaccines using polymer carriers
An integrated polymeric carrier for subunit cancer vaccines
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-11035141
This study is working on a new way to deliver cancer vaccines using a special material that helps the immune system recognize and fight melanoma better, with the hope that it will lead to more effective treatments for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11035141 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a polymer-based carrier for peptide cancer vaccines to enhance their effectiveness. By improving how these vaccines are formulated and delivered, the goal is to ensure that they are better recognized and processed by the immune system, specifically targeting dendritic cells. The study will involve optimizing the polymer structure, assessing how well the vaccine components are delivered, and testing their efficacy in a mouse model of melanoma. This approach aims to create a more reliable and potent cancer vaccine that could lead to better patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cancer who are seeking innovative immunotherapy options.
Not a fit: Patients who are not currently diagnosed with cancer or those who have contraindications to vaccination may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer vaccines that provide longer-lasting protection against tumors.
How similar studies have performed: Previous research has shown promise in using polymer carriers for vaccine delivery, indicating that this approach could be a significant advancement in cancer immunotherapy.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PUN, SUZIE H. — UNIVERSITY OF WASHINGTON
- Study coordinator: PUN, SUZIE H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer, anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy